HopeStage
Back to all studies
CompletedNCT00139919

Shorter bifeprunox dose titration in schizophrenia or bipolarity

About this title

Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder

Read the official source — NCT00139919
Medication studyAges 18–55United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 55 years.

Listed locations
OrangeSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJanuary 2006
Recruitment status
Completed
Enrollment listed in the registry
Not clearly listed
Sponsor
Solvay Pharmaceuticals
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 55 Years
Official registry ID
NCT00139919
Official title
Show the full official title

A Randomized, Double-Blind, Placebo-Controlled, Sequential Panel Study of the Safety and Tolerability of Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Either Schizophrenia or Bipolar Disorder With an Optional Open-Label 26-Week Extension Study

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Orange

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Solvay Pharmaceuticals.

Did this study involve medication?

Yes. The study involved medication, including Bifeprunox.

Who was this study for?

Listed age limits: 18 years to 55 years.

Want to explore more studies?

Explore studies